NASDAQ:STDY - Steadymed Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.7250 0.00 (0.00 %) (As of 10/19/2018 07:12 AM ET)Previous Close$4.7250Today's Range$4.7250 - $4.725052-Week Range$2.60 - $6.45Volume160 shsAverage Volume85,138 shsMarket Capitalization$126.36 millionP/E Ratio-10.99Dividend YieldN/ABeta0.47 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, water-resistant, and disposable drug administration technology. Its lead drug product candidate is Trevyent that is used for treating pulmonary arterial hypertension. The company also develops two drug product candidates for the treatment of post-surgical and acute pain in the home setting. It has operations in Israel, the United States, and Europe. SteadyMed Ltd. was founded in 2005 and is headquartered in San Ramon, California. Receive STDY News and Ratings via Email Sign-up to receive the latest news and ratings for STDY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:STDY CUSIPN/A Webwww.steadymed.com Phone925-272-4999 Debt Debt-to-Equity RatioN/A Current Ratio4.80 Quick Ratio4.80 Price-To-Earnings Trailing P/E Ratio-10.99 Forward P/E Ratio-6.22 P/E GrowthN/A Sales & Book Value Annual Sales$1.07 million Price / Sales118.08 Cash FlowN/A Price / CashN/A Book Value$0.16 per share Price / Book29.53 Profitability EPS (Most Recent Fiscal Year)($0.43) Net Income$-23,200,000.00 Net Margins-2,177.00% Return on Equity-94.69% Return on Assets-47.15% Miscellaneous Employees26 Outstanding Shares26,740,000Market Cap$126.36 million Steadymed (NASDAQ:STDY) Frequently Asked Questions What is Steadymed's stock symbol? Steadymed trades on the NASDAQ under the ticker symbol "STDY." How were Steadymed's earnings last quarter? Steadymed Ltd (NASDAQ:STDY) announced its quarterly earnings data on Tuesday, August, 14th. The company reported ($0.38) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.17. Steadymed had a negative return on equity of 94.69% and a negative net margin of 2,177.00%. View Steadymed's Earnings History. When is Steadymed's next earnings date? Steadymed is scheduled to release their next quarterly earnings announcement on Monday, November 12th 2018. View Earnings Estimates for Steadymed. What is the consensus analysts' recommendation for Steadymed? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Steadymed in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Steadymed. Who are some of Steadymed's key competitors? Some companies that are related to Steadymed include Zymeworks (ZYME), Aurinia Pharmaceuticals (AUPH), ArQule (ARQL), Aduro BioTech (ADRO), OptiNose (OPTN), Stemline Therapeutics (STML), Abeona Therapeutics (ABEO), TG Therapeutics (TGTX), MediciNova (MNOV), Theratechnologies (THERF), Progenics Pharmaceuticals (PGNX), Depomed (DEPO), Cytokinetics (CYTK), Corium International (CORI) and ZIOPHARM Oncology (ZIOP). Who are Steadymed's key executives? Steadymed's management team includes the folowing people: Mr. Jonathan M. N. Rigby, Pres, CEO & Director (Age 50)Mr. David W. Nassif, Exec. VP & CFO (Age 64)Mr. Robert Zwolinski, Sr. VP of OperationsMs. Marylyn Rigby, Sr. Director of Investor Relations and MarketingMr. Carl Hicks Jr., Editor & Chief of Bephenomental.com When did Steadymed IPO? (STDY) raised $56 million in an initial public offering (IPO) on Friday, March 20th 2015. The company issued 4,300,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager. How do I buy shares of Steadymed? Shares of STDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Steadymed's stock price today? One share of STDY stock can currently be purchased for approximately $4.7250. How big of a company is Steadymed? Steadymed has a market capitalization of $126.36 million and generates $1.07 million in revenue each year. The company earns $-23,200,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Steadymed employs 26 workers across the globe. What is Steadymed's official website? The official website for Steadymed is http://www.steadymed.com. How can I contact Steadymed? Steadymed's mailing address is 5 OPPENHEIMER STREET, REHOVOT L3, 7670105. The company can be reached via phone at 925-272-4999 or via email at [email protected] MarketBeat Community Rating for Steadymed (NASDAQ STDY)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 134 (Vote Outperform)Underperform Votes: 108 (Vote Underperform)Total Votes: 242MarketBeat's community ratings are surveys of what our community members think about Steadymed and other stocks. Vote "Outperform" if you believe STDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STDY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/19/2018 by MarketBeat.com StaffFeatured Article: What is a stock buyback?